Cellular senescence in the cholangiopathies

PURPOSE OF REVIEW: Cellular senescence, (i.e., permanent withdrawal from the cell cycle), is increasingly recognized as a pathologic feature in a variety of inflammatory liver diseases, including primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and additional cholangiopathies. Herein we provide an update on the interplay between cholangiocytes, cellular senescence, and the cholangiopathies. RECENT FINDINGS: The themes covered by this review include: i) novel models for studying the role of senescent cholangiocytes and the cholangiopathies, ii) identification and modulation of key pathways or molecules regulating cholangiocyte senescence, and iii) discovery of druggable targets to advance therapeutic options for the cholangiopathies. Most recent studies focused on PSC; however, the concepts and findings may be applied to additional cholangiopathies. SUMMARY: Cholangiopathies present unique and divergent clinicopathological features, etiologies, and genetic backgrounds, but share several common disease processes. Cholangiocyte senescence in the cholestatic cholangiopathies, primarily PSC and PBC, is regarded as a key pathogenetic process. Importantly, senescent cholangiocytes exhibit phenotypic features including the senescence-associated secretory phenotype (SASP) and resistance to apoptosis that provide new directions for basic research and new prognostic and therapeutic approaches for clinical practice.